Stocktoria
ADMA BIOLOGICS, INC. ADMA
ADMA BIOLOGICS, INC. (ADMA) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $510.2M at a 28.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -0.17 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.636 |
| Retained earnings / assets | -0.259 |
| EBIT / assets | 0.307 |
| Equity / liabilities | 3.249 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ADMA | ADMA BIOLOGICS, INC. | 5/9 | 8.8 | 13.8 | +19.6% |
| TARS | Tarsus Pharmaceuticals, Inc. | 4/9 | 2.84 | — | +146.7% |
| IMCR | Immunocore Holdings plc | 3/9 | 2.37 | — | +29% |
| KRYS | Krystal Biotech, Inc. | 5/9 | 16.61 | 53.6 | +33.9% |
| TWST | Twist Bioscience Corp | 3/9 | -2.72 | — | +20.3% |
| RGEN | REPLIGEN CORP | 6/9 | 5.48 | 169.6 | +16.4% |
| VCEL | Vericel Corp | 7/9 | 3.1 | 118.9 | +16.5% |
About ADMA BIOLOGICS, INC.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
FAQ
Is ADMA financially healthy?
ADMA BIOLOGICS, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ADMA pay a dividend?
No, ADMA BIOLOGICS, INC. does not currently pay a dividend.
How profitable is ADMA?
In FY2025, ADMA BIOLOGICS, INC. had a net margin of 28.8% and a return on equity of 30.8%.
What is ADMA's P/E ratio?
ADMA BIOLOGICS, INC.'s trailing price-to-earnings (P/E) ratio is about 13.8×, based on its latest annual earnings.
What is the analyst price target for ADMA?
The average Wall-Street price target for ADMA BIOLOGICS, INC. is $17.60, about 80.0% above the recent price, from 5 analysts (consensus: buy).
Is ADMA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ADMA BIOLOGICS, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 13.8×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.